Lista de obras -

A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

scientific article published on 03 October 2018

A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models

artículo científico publicado en 2008

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

artículo científico publicado en 2006

Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.

artículo científico publicado en 2004

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.

artículo científico publicado en 2015

Characterization of host immunity to cytomegalovirus pp150 (UL32).

artículo científico publicado en 2005

Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice

artículo científico publicado en 2011

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant

artículo científico publicado en 2012

Correction for Chiuppesi et al., "Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice"

artículo científico publicado en 2019

Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.

artículo científico publicado en 2013

Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients

artículo científico publicado en 2014

Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients

artículo científico publicado en 2006

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex

artículo científico publicado en 2014

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge ⬇️

artículo científico publicado el 15 de octubre de 2003

In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara

artículo científico

Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses

artículo científico publicado en 2010

La Rosa C et al (J Infect Dis 2012; 205:1294–304).

artículo científico publicado en 2013

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease

artículo científico publicado en 2007

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults

artículo científico publicado en 2016

Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development

artículo científico publicado en 2009

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

artículo científico publicado en 2009

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

scholarly article by Flavia Chiuppesi et al published 1 October 2018 in Journal of Virology

Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients

artículo científico publicado en 2016

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial

artículo científico publicado en 2020

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

artículo científico publicado en 2002

Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients

artículo científico publicado en 2011

Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease.

artículo científico publicado en 2008

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax

scientific article published on 16 December 2018

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

artículo científico publicado en 2004

Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV.

artículo científico publicado en 2005

Relative dominance of HLA-B07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A02 and HLA-B*07 alleles

artículo científico publicado en 2003

The immune response to human CMV

artículo científico publicado en 2012

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

artículo científico publicado en 2006

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial

artículo científico publicado en 2015

Lista de obras de

A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.

Characterization of host immunity to cytomegalovirus pp150 (UL32).

Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant

Correction for Chiuppesi et al., "Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice"

Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.

Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients

Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge ⬇️

In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara

Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses

La Rosa C et al (J Infect Dis 2012; 205:1294–304).

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults

Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients

Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV.

Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles

The immune response to human CMV

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial

Relative dominance of HLA-B07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A02 and HLA-B*07 alleles